50 results on '"Stefka, Andrew"'
Search Results
2. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
3. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
4. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
5. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
6. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
7. Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens
8. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
9. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
10. Phase 1/2 study of carfilzomib, pomalidomide, dexamethasone with and without daratumumab in relapsed multiple myeloma
11. Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)
12. Commensal bacteria protect against food allergen sensitization
13. The composition of the microbiota modulates allograft rejection
14. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent
15. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
16. A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
17. Abstract 2394: tRNA expression and tRFs in multiple myeloma: Progression from monoclonal gammopathies to relapsed/refractory disease
18. Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
19. Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).
20. P-397 Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide
21. Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study
22. Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.
23. Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
24. Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models.
25. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
26. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
27. Bacterial metabolites reduce intestinal permeability to protect against food allergen sensitization (MUC8P.724)
28. DCE-MRI-derived microvasculature mapping and outcome prediction in patients with breast cancer.
29. Oral administration of butyrate protects against sensitization to cow milk protein in a murine model of cow milk allergy
30. Lactobacillus rhamnosus GG intervention expands tolerogenic microbiota in infants with cow's milk allergy
31. TLR4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+ Tregs during intestinal inflammation
32. Tlr4 regulates IFNγ and IL-17 production by both natural and induced Foxp3+ Tregs in the inflamed intestine during intestinal inflammation (P3276)
33. Commensal bacteria induce a barrier protective response to prevent sensitization to food allergens (P6037)
34. Microbial regulation of allergic responses to food
35. 1077 TLR4 Regulates IFNy and IL-17 Production by Both Natural and Induced FOXP3+ Tregs in the Inflamed Intestine
36. Antibiotic induced alterations in the commensal microbiome reduce CD4+Foxp3+ Tregs in the colonic lamina propria and increase allergic responses to food (175.14)
37. Tlr4-/- mice have reduced proportions of CD4+Foxp3+ Tregs in the colonic lamina propria and increased susceptibility to allergic responses to food (175.20)
38. Commensal bacteria regulate Treg abundance in a gnotobiotic model of food allergy. (120.6)
39. Regulation of the Polymeric Immunoglobulin Receptor in Intestinal Epithelial Cells byEnterobacteriaceae: Implications for Mucosal Homeostasis
40. Toll-Like Receptor 4-Mediated Regulation of Spontaneous Helicobacter-Dependent Colitis in IL-10–Deficient Mice
41. W1627 TLR4 Mediated Regulation of Spontaneous Colitis in IL-10 Deficient Mice
42. Dysregulated expression patterns of pro‐and anti‐inflammatory biomarkers in the intestinal mucosa define phenotypic subsets of Crohn's Disease
43. MyD88-dependent regulation of the polymeric immunoglobulin receptor by colonic microbes (40.5)
44. Lactobacillus rhamnosusGG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
45. Regulation of the Polymeric Immunoglobulin Receptor in Intestinal Epithelial Cells by Enterobacteriaceae: Implications for Mucosal Homeostasis.
46. TLR4 regulates IFN‐γ and IL‐17 production by both thymic and induced Foxp3+Tregsduring intestinal inflammation
47. Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models
48. High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial
49. The composition of the microbiota modulates allograft rejection.
50. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.